

Ippei Kanazawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1917281/publications.pdf>

Version: 2024-02-01

87
papers

3,402
citations

147801

31
h-index

149698

56
g-index

93
all docs

93
docs citations

93
times ranked

3903
citing authors

#	ARTICLE	IF	CITATIONS
1	Higher Serum Uric Acid is a Risk Factor of Reduced Muscle Mass in Men with Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 50-55.	1.2	13
2	High glucose promotes mineralization via bone morphogenetic protein 4-Smad signals in early stage of osteoblast differentiation. <i>Diabetology International</i> , 2021, 12, 171-180.	1.4	6
3	Response to the letter from Otsuka et al. Trends in the prevalence of underweight in women across generations in Japan. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 721-722.	2.7	0
4	Which Is a Better Skeletal Muscle Mass Index for the Evaluation of Physical Abilities: The Present Height or Maximum Height?. <i>Internal Medicine</i> , 2021, 60, 1191-1196.	0.7	3
5	Higher Serum Uric Acid is a Risk Factor of Vertebral Fractures in Postmenopausal Women with Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020, 128, 66-71.	1.2	4
6	Executive summary of clinical practice guide on fracture risk in lifestyle diseases. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 746-758.	2.7	8
7	Modulators of Fam210a and Roles of Fam210a in the Function of Myoblasts. <i>Calcified Tissue International</i> , 2020, 106, 533-540.	3.1	7
8	Bazedoxifene Ameliorates Homocysteine-Induced Apoptosis via NADPH Oxidase-Interleukin 1 β and 6 Pathway in Osteocyte-like Cells. <i>Calcified Tissue International</i> , 2019, 105, 446-457.	3.1	5
9	Phloretin Suppresses Bone Morphogenetic Protein-2-Induced Osteoblastogenesis and Mineralization via Inhibition of Phosphatidylinositol 3-kinases/Akt Pathway. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2481.	4.1	14
10	Low skeletal muscle mass is associated with the risk of all-cause mortality in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881984297.	3.2	27
11	A scoring assessment tool for the risk of vertebral fractures in patients with type 2 diabetes mellitus. <i>Bone</i> , 2019, 122, 38-44.	2.9	4
12	Insulin-Like Growth Factor-I Protects Against the Detrimental Effects of Advanced Glycation End Products and High Glucose in Myoblastic C2C12 Cells. <i>Calcified Tissue International</i> , 2019, 105, 89-96.	3.1	15
13	Osteoporosis and vertebral fracture are associated with deterioration of activities of daily living and quality of life in patients with type 2 diabetes mellitus. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 503-511.	2.7	23
14	Overweight and underweight are risk factors for vertebral fractures in patients with type 2 diabetes mellitus. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 703-710.	2.7	11
15	FAM210A is a novel determinant of bone and muscle structure and strength. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3759-E3768.	7.1	49
16	Osteoblast AMP-Activated Protein Kinase Regulates Postnatal Skeletal Development in Male Mice. <i>Endocrinology</i> , 2018, 159, 597-608.	2.8	17
17	Diabetes and Osteoporosis. , 2018, , 127-139.		0
18	Association of Bone Mineral Density, Bone Turnover Markers, and Vertebral Fractures with All-Cause Mortality in Type 2 Diabetes Mellitus. <i>Calcified Tissue International</i> , 2018, 102, 1-13.	3.1	41

#	ARTICLE	IF	CITATIONS
19	Glucose uptake inhibition decreases expressions of receptor activator of nuclear factor-kappa B ligand (RANKL) and osteocalcin in osteocytic MLO-Y4-A2 cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 314, E115-E123.	3.5	18
20	Nerve conduction velocity is negatively associated with intima-media thickness and brachial-ankle pulse wave velocity in men with type 2 diabetes mellitus. <i>PLoS ONE</i> , 2018, 13, e0209503.	2.5	2
21	Albuminuria Increases All-Cause Mortality in Japanese Patients with Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2018, 7, 234.	2.4	4
22	Diabetes Mellitus-induced Bone Fragility. <i>Internal Medicine</i> , 2018, 57, 2773-2785.	0.7	37
23	Prehypertension increases the risk of atherosclerosis in drug-naïve Japanese patients with type 2 diabetes mellitus. <i>PLoS ONE</i> , 2018, 13, e0201055.	2.5	5
24	The Association Between Osteocalcin and Chronic Inflammation in Patients with Type 2 Diabetes Mellitus. <i>Calcified Tissue International</i> , 2018, 103, 599-605.	3.1	13
25	Osteoblast AMP-activated protein kinase regulates glucose metabolism and bone mass in adult mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1955-1961.	2.1	8
26	Visceral fat accumulation is associated with increased plasma sphingosine-1-phosphate levels in type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 146-150.	2.8	16
27	Phloretin Promotes Adipogenesis via Mitogen-Activated Protein Kinase Pathways in Mouse Marrow Stromal ST2 Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1772.	4.1	21
28	Assessment using serum insulin-like growth factor-I and bone mineral density is useful for detecting prevalent vertebral fractures in patients with type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2018, 29, 2527-2535.	3.1	18
29	Vitamin D-mediated hypercalcemia in multicentric Castleman's disease. <i>Journal of Bone and Mineral Metabolism</i> , 2017, 35, 122-125.	2.7	0
30	Advanced Glycation End Product 3 (AGE3) Increases Apoptosis and the Expression of Sclerostin by Stimulating TGF- β 2 Expression and Secretion in Osteocyte-Like MLO-Y4-A2 Cells. <i>Calcified Tissue International</i> , 2017, 100, 402-411.	3.1	25
31	Bazedoxifene Ameliorates Homocysteine-Induced Apoptosis and Accumulation of Advanced Glycation End Products by Reducing Oxidative Stress in MC3T3-E1 Cells. <i>Calcified Tissue International</i> , 2017, 100, 286-297.	3.1	25
32	Association of osteoglycin and FAM5C with bone turnover markers, bone mineral density, and vertebral fractures in postmenopausal women with type 2 diabetes mellitus. <i>Bone</i> , 2017, 95, 5-10.	2.9	8
33	Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment. <i>Diabetes Research and Clinical Practice</i> , 2017, 123, 9-17.	2.8	14
34	Association of the roles of advanced glycation end products and osteocalcin between bone metabolism and vascular failure. <i>Vascular Failure</i> , 2017, 1, 30-38.	0.2	1
35	Interaction between bone and glucose metabolism [Review]. <i>Endocrine Journal</i> , 2017, 64, 1043-1053.	1.6	69
36	Decreased Serum Insulin-like Growth Factor-I is a Risk Factor for Non-vertebral Fractures in Diabetic Postmenopausal Women. <i>Internal Medicine</i> , 2017, 56, 269-273.	0.7	17

#	ARTICLE	IF	CITATIONS
37	Elevated Serum Pentosidine and Decreased Serum IGF-I Levels are Associated with Loss of Muscle Mass in Postmenopausal Women with Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2016, 124, 163-166.	1.2	25
38	Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 1-6.	2.8	15
39	Simvastatin rescues homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by decreasing the expressions of NADPH oxidase 1 and 2. <i>Endocrine Journal</i> , 2016, 63, 389-395.	1.6	15
40	Decreased serum insulin-like growth factor-I level is associated with the increased mortality in type 2 diabetes mellitus. <i>Endocrine Journal</i> , 2016, 63, 811-818.	1.6	9
41	Reduced muscle mass and accumulation of visceral fat are independently associated with increased arterial stiffness in postmenopausal women with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2016, 122, 141-147.	2.8	25
42	Serum dipeptidyl peptidase-4 is associated with multiple vertebral fractures in type 2 diabetes mellitus. <i>Clinical Endocrinology</i> , 2016, 84, 332-337.	2.4	9
43	Activation of AMP-activated protein kinase decreases receptor activator of NF- κ B ligand expression and increases sclerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 791-796.	2.1	18
44	Osteocalcin as a hormone regulating glucose metabolism. <i>World Journal of Diabetes</i> , 2015, 6, 1345.	3.5	81
45	Osteoblast Menin Regulates Bone Mass in Vivo. <i>Journal of Biological Chemistry</i> , 2015, 290, 3910-3924.	3.4	29
46	Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 461, 193-199.	2.1	145
47	Activation of AMP-activated protein kinase protects against homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by regulating the expressions of NADPH oxidase 1 (Nox1) and Nox2. <i>Bone</i> , 2015, 77, 135-141.	2.9	35
48	Reduction in Endogenous Insulin Secretion is a Risk Factor of Sarcopenia in Men with Type 2 Diabetes Mellitus. <i>Calcified Tissue International</i> , 2015, 97, 385-390.	3.1	44
49	Pioglitazone Increases Serum DPP-4 Level in Type 2 Diabetes Mellitus. <i>Journal of Diabetes & Metabolism</i> , 2014, 05, .	0.2	1
50	Advanced Glycation End Product 3 (AGE3) Suppresses the Mineralization of Mouse Stromal ST2 Cells and Human Mesenchymal Stem Cells by Increasing TGF- β 2 Expression and Secretion. <i>Endocrinology</i> , 2014, 155, 2402-2410.	2.8	56
51	Active vitamin D possesses beneficial effects on the interaction between muscle and bone. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 482-487.	2.1	62
52	Serum osteocalcin levels are inversely associated with abdominal aortic calcification in men with type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2013, 24, 2223-2230.	3.1	31
53	Undercarboxylated osteocalcin is positively associated with free testosterone in male patients with type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2013, 24, 1115-1119.	3.1	45
54	Advanced glycation end products suppress osteoblastic differentiation of stromal cells by activating endoplasmic reticulum stress. <i>Biochemical and Biophysical Research Communications</i> , 2013, 438, 463-467.	2.1	37

#	ARTICLE	IF	CITATIONS
55	Adiponectin in Metabolic Bone Disease. <i>Current Medicinal Chemistry</i> , 2012, 19, 5481-5492.	2.4	44
56	Antiosteoporotic Drugs and Incidence of Type 2 Diabetes Mellitus. <i>Calcified Tissue International</i> , 2012, 90, 163-164.	3.1	0
57	Effects of intensive glycemic control on serum levels of insulin-like growth factor-I and dehydroepiandrosterone sulfate in Type 2 diabetes mellitus. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 469-72.	3.3	11
58	Relationship between bone biochemical markers versus glucose/lipid metabolism and atherosclerosis; a longitudinal study in type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2011, 92, 393-399.	2.8	37
59	Serum insulin-like growth factor-I is negatively associated with serum adiponectin in type 2 diabetes mellitus. <i>Growth Hormone and IGF Research</i> , 2011, 21, 268-271.	1.1	20
60	Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. <i>Bone</i> , 2011, 48, 720-725.	2.9	117
61	Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus. <i>Clinical Endocrinology</i> , 2011, 74, 467-472.	2.4	21
62	Serum calcium is positively correlated with fasting plasma glucose and insulin resistance, independent of parathyroid hormone, in male patients with type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1334-1339.	3.4	55
63	Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2011, 22, 187-194.	3.1	223
64	Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2011, 22, 1191-1198.	3.1	63
65	Effects of Metformin and Pioglitazone on Serum Pentosidine Levels in Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011, 119, 362-365.	1.2	35
66	Fasudil hydrochloride induces osteoblastic differentiation of stromal cell lines, C3H10T1/2 and ST2, via bone morphogenetic protein-2 expression. <i>Endocrine Journal</i> , 2010, 57, 415-421.	1.6	13
67	Effects of Treatment With Risedronate and Alfacalcidol on Progression of Atherosclerosis in Postmenopausal Women With Type 2 Diabetes Mellitus Accompanied With Osteoporosis. <i>American Journal of the Medical Sciences</i> , 2010, 339, 519-524.	1.1	23
68	Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2010, 21, 2013-2018.	3.1	35
69	Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 554-560.	2.7	88
70	Baseline serum total adiponectin level is positively associated with changes in bone mineral density after 1-year treatment of type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1252-1256.	3.4	27
71	Relationships between dimethylarginine and the presence of vertebral fractures in type 2 diabetes mellitus. <i>Clinical Endocrinology</i> , 2010, 73, 463-468.	2.4	7
72	Inhibition of the Mevalonate Pathway Rescues the Dexamethasone-induced Suppression of the Mineralization in Osteoblasts via Enhancing Bone Morphogenetic Protein-2 Signal. <i>Hormone and Metabolic Research</i> , 2009, 41, 612-616.	1.5	8

#	ARTICLE	IF	CITATIONS
73	Adiponectin Is Associated with Changes in Bone Markers during Glycemic Control in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3031-3037.	3.6	80
74	Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 296, E139-E146.	3.5	82
75	Serum Osteocalcin Level Is Associated with Glucose Metabolism and Atherosclerosis Parameters in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 45-49.	3.6	381
76	Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. <i>European Journal of Endocrinology</i> , 2009, 160, 265-273.	3.7	92
77	Serum Osteocalcin/Bone-Specific Alkaline Phosphatase Ratio Is a Predictor for the Presence of Vertebral Fractures in Men with Type 2 Diabetes. <i>Calcified Tissue International</i> , 2009, 85, 228-234.	3.1	52
78	Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. <i>Bone</i> , 2009, 45, 174-179.	2.9	124
79	Osteosarcoma in a pregnant patient with McCune-Albright syndrome. <i>Bone</i> , 2009, 45, 603-608.	2.9	25
80	Rosuvastatin Increased Serum Osteocalcin Levels Independent of Its Serum Cholesterol-Lowering Effect in Patients with Type 2 Diabetes and Hypercholesterolemia. <i>Internal Medicine</i> , 2009, 48, 1869-1873.	0.7	22
81	A case of membranous nephropathy associated with chronic sinusitis. <i>Journal of Nephrology</i> , 2009, 22, 289-94.	2.0	2
82	Combination of Obesity with Hyperglycemia is a Risk Factor for the Presence of Vertebral Fractures in Type 2 Diabetic Men. <i>Calcified Tissue International</i> , 2008, 83, 324-331.	3.1	53
83	Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. <i>Biochemical and Biophysical Research Communications</i> , 2008, 375, 414-419.	2.1	188
84	Serum DHEA-S Level Is Associated with the Presence of Atherosclerosis in Postmenopausal Women with Type 2 Diabetes Mellitus. <i>Endocrine Journal</i> , 2008, 55, 667-675.	1.6	28
85	Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. <i>BMC Cell Biology</i> , 2007, 8, 51.	3.0	155
86	Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2007, 18, 1675-1681.	3.1	54
87	Cu/Zn superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson disease: a light and electron microscopic immunocytochemical study. <i>Acta Neuropathologica</i> , 1995, 89, 471-474.	7.7	5